Boardroom Alpha
Boardroom Alpha
BNGO · Additional Proxy Materials (DEFA14A) · Filed April 2, 2026

Bionano Genomics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 2, 2026
Ticker
BNGO
Accession
0001411690-26-000015
Boardroom Alpha · Filing insights

Bionano Genomics' board urges stockholders to vote FOR Proposals 1-3 (director elections, executive compensation advisory vote, auditor ratification).

About Bionano Genomics Inc
Market cap
$15M
1Y TSR
−65.7%
3Y TSR
−82.8%
Board grade
D
Sector
Healthcare
CEO
Albert Luderer
Last annual meeting: May 14, 2026 · View full Bionano Genomics Inc profile →
DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant

Check the appropriate box:

 

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material Pursuant to § 240.14a-12

 

Bionano Genomics, Inc.

(Name of Registrant as Specified in its Charter)

 

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

 

No fee required.

 

 

Fee paid previously with preliminary materials.

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 


 

img93053740_0.jpg

 


 

 

styleINAstyleINA P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! BIONANO GENOMICS, INC. Annual Meeting of Stockholders Thursday, May 14, 2026 10:00 AM, Pacific Time Annual meeting to be held via the internet - please visit www.proxydocs.com/BNGO You must register to attend the meeting online and/or participate at www.proxydocs.com/BNGO Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 14, 2026 For Stockholders of record as of March 19, 2026 To order paper materials, use one of the following methods. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/BNGO To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 4, 2026. Internet: www.investorelections.com/BNGO Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved

 


 

img93053740_1.jpg

 


 

BIONANO GENOMICS, INC. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 PROPOSAL 1. Election of Class II Directors 1.01 Albert Luderer, Ph.D. 1.02 Kristiina Vuori, M.D., Ph.D. 2. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. 3. To ratify the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Bionano Genomics Inc (BNGO)

Reference

Frequently asked questions

When did Bionano Genomics Inc file this DEFA14A?
Bionano Genomics Inc (BNGO) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 2, 2026. The accession number assigned by EDGAR is 0001411690-26-000015.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Bionano Genomics' board urges stockholders to vote FOR Proposals 1-3 (director elections, executive compensation advisory vote, auditor ratification). This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Bionano Genomics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Bionano Genomics Inc has filed under CIK 1411690, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer